Axsome Therapeutics Income Statement (2022-2025) | AXSM

Income Statement Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue 16.85M24.37M94.58M46.70M57.79M71.53M75.00M87.17M104.76M118.77M121.46M150.04M170.99M
Cost of Revenue 1.92M2.29M7.56M4.60M6.53M7.38M6.30M8.05M8.44M10.51M9.79M13.45M11.91M
Gross Profit 14.92M22.08M87.02M42.10M51.26M64.15M68.70M79.11M96.33M108.25M111.67M136.59M159.08M
Operating items
Amortization - Intangibles 1.61M1.61M1.60M1.59M1.61M1.61M1.59M1.59M1.61M1.61M1.57M1.59M1.61M
Research & Development 12.59M15.79M14.88M14.69M17.79M20.58M28.77M30.80M36.83M49.85M45.39M55.01M44.78M49.54M40.16M
Selling, General & Administrative 25.70M31.16M40.89M61.50M74.19M78.94M83.19M86.81M98.97M103.55M95.56M113.27M120.79M130.28M150.24M
Other Operating Expenses 1.05M-45.29M-0.06M-0.06M12.24M7.96M52.19M6.47M11.80M26.43M23.11M12.87M6.93M26.70M
Operating Expenses 38.29M48.00M59.26M84.29M100.95M111.76M119.91M169.80M142.27M165.21M167.39M191.38M178.44M186.76M217.10M
Operating Income -38.29M-39.18M-42.41M-59.92M-6.37M-65.06M-62.12M-98.27M-67.28M-78.05M-62.62M-72.62M-56.98M-36.71M-46.11M
EBIT -38.29M-39.18M-42.41M-59.92M-6.37M-65.06M-62.12M-98.27M-67.28M-78.05M-62.62M-72.62M-56.98M-36.71M-46.11M
Non-operating items
Interest & Investment Income -1.34M-2.26M-2.41M-1.32M-2.26M-2.73M-0.76M-0.70M-1.08M-1.30M-1.98M-2.21M-2.43M-1.83M-1.12M
Net income details
EBT -39.63M-41.44M-44.82M-61.24M-8.64M-67.79M-62.88M-98.98M-68.36M-79.34M-64.60M-74.83M-59.41M-48.93M-47.23M
Tax Provisions 2.60M-0.62M-0.70M-0.34M0.09M-1.00M
Profit After Tax -39.63M-41.44M-44.82M-61.24M-11.22M-67.17M-62.20M-98.65M-68.36M-79.34M-64.60M-74.91M-59.41M-47.97M-47.23M
Income from Continuing Operations -39.63M-41.44M-44.82M-61.24M-11.24M-67.17M-62.18M-98.64M-68.36M-79.34M-64.60M-74.91M-59.41M-47.93M-47.23M
Consolidated Net Income -39.63M-41.44M-44.82M-61.24M-11.24M-67.17M-62.18M-98.64M-68.36M-79.34M-64.60M-74.91M-59.41M-47.93M-47.23M
Income towards Parent Company -39.63M-41.44M-44.82M-61.24M-11.24M-67.17M-62.18M-98.64M-68.36M-79.34M-64.60M-74.91M-59.41M-47.93M-47.23M
Net Income towards Common Stockholders -39.63M-41.44M-44.82M-61.24M-11.24M-67.17M-62.18M-98.64M-68.36M-79.34M-64.60M-74.91M-59.41M-47.93M-47.23M
Additional items
EPS (Basic) -1.03-1.06-1.07-1.43-0.26-1.54-1.32-2.13-1.44-1.67-1.34-1.54-1.22-0.97-0.94
EPS (Weighted Average and Diluted) -1.03-1.06-1.07-1.43-0.26-1.54-1.32-2.13-1.44-1.67-1.34-1.54-1.22-0.97-0.94
Shares Outstanding (Weighted Average) 38.48M38.91M40.30M43.43M43.52M43.57M47.19M47.32M47.37M47.50M48.00M48.46M48.77M49.24M49.90M
Shares Outstanding (Diluted Average) 38.32M39.08M41.70M40.66M43.52M43.67M47.12M45.43M47.39M47.57M48.14M47.91M48.87M49.44M50.02M
EBITDA -38.29M-39.18M-42.41M-59.92M-6.37M-65.06M-62.12M-98.27M-67.28M-78.05M-62.62M-72.62M-56.98M-36.71M-46.11M
Tax Rate 0.91%1.11%0.34%2.04%